AIGIV treatment for systemic anthrax: an observational study
Part of Infections clinical trials.
This study looks at patients who have been diagnosed with or are suspected to have systemic anthrax and are being treated with the medicine AIGIV. It aims to understand how well the treatment works and whether it is safe. The results may help improve care for people with this serious infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed or suspected systemic anthrax (infection throughout the body).
- You must be treated with AIGIV, which is provided by the Centers for Disease Control and Prevention (CDC).
- Your condition must match one of the defined types of anthrax: gastrointestinal, injectional, inhalational, meningitis, bacteremia, or severe skin anthrax.
- There must be laboratory evidence of the anthrax bacteria, such as a positive culture, antigen test, PCR, or other approved test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment called AIGIV (sometimes sold as Anthrasil) for people who get anthrax by breathing in the germs. The treatment is made from human antibodies that fight the anthrax toxin, and the study checks if it is safe and helps patients recover.
This study observes people in the US who have been diagnosed with systemic anthrax and treated with a medication called raxibacumab, which was given from a national emergency supply. The goal is to learn more about how this treatment works in real-world cases.
This study is for people who have symptoms of inhalational anthrax after a mass exposure. It tests a medicine called raxibacumab to see if it helps and is safe. Anyone who receives this medicine as part of their care can join.
This trial looks at how well a medicine called VIGIV works for people who develop serious or unusual vaccinia (smallpox-type) infections or complications after smallpox vaccination. It is mainly for specific skin and body-area problems, including eczema-related complications.
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Hear when a new Anthrax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.